Metyrapone‐induced withdrawal symptoms
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The metyrapone test is widely used in endocrinological testing to assess the integrity of hypothalamic‐pituitary‐adrenal axis function; we have used it to study the metabolic basis of addictive disease and opioid dependence. In recent studies, we have observed that metyrapone administration in long‐term methadone‐maintained patients and in patients undergoing slow dose reduction to drug‐free status following chronic treatment may induce a narcotic withdrawal‐like syndrome. Although metyrapone is known to produce mild adverse reactions in non‐opiate dependent subjects, narcotic withdrawal‐like symptoms have not been previously observed or reported. The metyrapone test was administered to 15 former heroin addicts: 10 (8 male, 2 female) in steady‐state methadone maintenance therapy (30 to 90 mg/d) and 5 (3 male, 2 female) in the final phase of a slow methadone dose reduction procedure (0 to 10 mg/d). Eight out of 15 methadone maintenance subjects exhibited a narcotic withdrawal‐like syndrome ranging from ‘moderate’ to “severe’ and four additional subjects had‘mild’ symptoms, occurring within 1 h after metyrapone administration, and resolving within 2 h of onset. No significant symptoms were seen in 3 methadone maintained subjects nor in any of 9 normal volunteers (7 male, 2 female). The mechanism by which metyrapone induces symptoms resembling narcotic withdrawal in opiate‐dependent individuals is unknown but physicians performing this test should be aware of this possible response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cushing's syndrome: a review of diagnostic tests.
Crapo, L. (1979) · Metabolism · doi:10.1016/0026-0495(79)90097-0 · Cited by 393
Medical safety and side effects of methadone in tolerant individuals
Kreek, M. J. (1973) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1973.03220060039009 · Cited by 247
Self-citationKreek, M. J., Wardlaw, S. L., Hartman, N., Raghunath, J., Friedman, J., Schneider, B., & Frantz, A. G. (1983) · Life Sciences · doi:10.1016/0024-3205(83)90529-5 · Cited by 92
Self-citation
Cited by
Bond, C., LaForge, K. S., Tian, M., Melia, D., Zhang, S., Borg, L., Gong, J., Schluger, J., Strong, J. A., Leal, S. M., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.16.9608 · Cited by 1,074
Self-citationDrug dependence: stress and dysregulation of brain reward pathways
Kreek, M. J., & Koob, G. F. (1998) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(98)00064-7 · Cited by 696
Self-citationMaintenance Medication for Opiate Addiction: The Foundation of Recovery
Bart, G. (2012) · Journal of Addictive Diseases · doi:10.1080/10550887.2012.694598 · Cited by 461
“30 While pharmacotherapy may not correct alterations in dopamine receptor availability and opioid gene expression, it does appear to normalize several aspects of stress responsiveness.”
BackgroundKreek, M. J., LaForge, K. S., & Butelman, E. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd897 · Cited by 374
Self-citationKREEK, M. J. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06683.x · Cited by 258
Self-citation
Metadata
- Authors
- KENNEDY, J. A., HARTMAN, N., SBRIGLIO, R., KHURI, E., & KREEK, M. J.
- Venue
- British Journal of Addiction
- Publisher
- Wiley
- Published
- 1990-09
- Volume
- 85
- Issue
- 9
- Pages
- 1133-1140
- ISSN
- 0952-0481 (ISSN-L)
- 2056-5178
- OpenAlex
- W1976889710
- Cited by
- 33
- References
- 3
- FWCI
- 1.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metyrapone‐induced withdrawal symptoms. https://app.cochat.ai/papers/10.1111/j.1360-0443.1990.tb03438.x
- The paper
- KENNEDY, J. A., HARTMAN, N., SBRIGLIO, R., KHURI, E., & KREEK, M. J. (1990). Metyrapone‐induced withdrawal symptoms. British Journal of Addiction. https://doi.org/10.1111/j.1360-0443.1990.tb03438.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.